Phase 1 Recruiting

PYC-003

Antisense Gene Therapy Targeting the Root Cause of PKD

Sponsor

PYC Therapeutics

Trial Name

First-in-Human PKD1

Start Date

2025-04

Est. Completion

2027

Participants

116

Location

Perth, Australia

NCT ID

NCT06714006

Mechanism

Peptide-PMO conjugate antisense therapy targeting PKD1 mutations, delivered IV

PYC-003 from PYC Therapeutics uses peptide-conjugated antisense technology to directly target PKD1 gene mutations — a precision medicine approach that could correct the underlying genetic defect.

Background

PYC Therapeutics is an Australian company specializing in peptide-PMO (phosphorodiamidate morpholino oligomer) conjugates — antisense molecules that can enter cells more efficiently than traditional antisense drugs. PYC-003 targets PKD1 mutations directly, aiming to restore functional polycystin-1 production. This is one of only two drugs in the pipeline (alongside farabursen) that addresses the genetic root cause rather than downstream effects.

How It Works

PYC-003 is a peptide-conjugated PMO antisense oligonucleotide. PMOs work by binding to pre-mRNA and modulating splicing — in this case, likely skipping exons containing disease-causing mutations in the PKD1 gene to restore a partially functional, shorter polycystin-1 protein (similar to the approach used in Duchenne muscular dystrophy). The peptide conjugation is PYC's proprietary technology that enhances cellular uptake and kidney delivery.

Clinical Trial Details

The Phase 1 first-in-human study (NCT06714006) has three parts: single ascending doses in healthy volunteers, then single ascending doses in ADPKD patients, then multiple ascending doses in ADPKD patients. Total enrollment target is 116 participants. Sites in Australia and New Zealand. Started April 2025 with estimated completion in 2027.

Why It's Promising

If PYC-003 can restore even partial polycystin-1 function, it would be addressing the fundamental defect in ADPKD. The PMO platform has proven effective in other genetic diseases. The large enrollment (116 for Phase 1) suggests thorough dose-finding. Combined with farabursen, there could be two independent genetic approaches reaching market.

Limitations & Concerns

Very early stage (Phase 1). Antisense drugs often struggle with kidney delivery — most accumulate in liver. IV administration required. Mutation-specific approaches may only work for subset of PKD1 patients. Long timeline (8–12 years to market).

gene-therapy first-in-class root-cause australia

Disclaimer: This information is for educational purposes only and is not medical advice. Clinical trial information is based on publicly available data from ClinicalTrials.gov and published research. Consult your nephrologist before making treatment decisions.